Log in to save to my catalogue

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5754190

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a
FLT3
mutation. Among patients with acute myeloid leukemia and this mutation, the addition of midostaurin to standard chemotherapy appeared to improve long-term outcomes.

Alternative Titles

Full title

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5754190

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5754190

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1614359

How to access this item